Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification

• Published in: British journal of cancer Vol. 112; no. 2; pp. 290 - 295
• Main Authors: Defferrari, R, Mazzocco, K, Ambros, I M, Ambros, P F, Bedwell, C, Beiske, K, Bénard, J, Berbegall, A P, Bown, N, Combaret, V, Couturier, J, Erminio, G, Gambini, C, Garaventa, A, Gross, N, Haupt, R, Kohler, J, Jeison, M, Lunec, J, Marques, B, Martinsson, T, Noguera, R, Parodi, S, Schleiermacher, G, Tweddle, D A, Valent, A, Van Roy, N, Vicha, A, Villamon, E, Tonini, G P
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 20.01.2015; Nature Publishing Group
• Subjects: 631/208/2489/1381; 692/4028/67/1922; 692/53/2422; 692/700/1720; ACCUMULATION; aCGH; Biomedical and Life Sciences; Biomedicine; Cancer and Oncology; Cancer och onkologi; Cancer Research; Chromosome Aberrations; Clinical Study; COMMITTEE; Comparative Genomic Hybridization; Disease-Free Survival; Drug Resistance; Epidemiology; Gene Amplification; HIGH-RISK NEUROBLASTOMA; Humans; Infant; ITALIAN EXPERIENCE; Kaplan-Meier Estimate; localised; MLPA; Molecular Medicine; N-MYC; N-Myc Proto-Oncogene Protein; neuroblastoma; Neuroblastoma - diagnosis; Neuroblastoma - genetics; Neuroblastoma - mortality; Nuclear Proteins - genetics; Oncogene Proteins - genetics; Oncology; ONCOLOGY GROUP; PATHOLOGY; Peripheral Nervous System Neoplasms - diagnosis; Peripheral Nervous System Neoplasms - genetics; Peripheral Nervous System Neoplasms - mortality; PROGNOSIS; PROGRESSION; segmental chromosome alterations; STRATIFICATION; unresectable; neuroblastoma; segmental chromosome alterations; MLPA; aCGH; localised; unresectable
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.2014.557

Background: The prognostic impact of segmental chromosome alterations (SCAs) in children older than 1 year, diagnosed with localised unresectable neuroblastoma (NB) without MYCN amplification enrolled in the European Unresectable Neuroblastoma (EUNB) protocol is still to be clarified, while, for other group of patients, the presence of SCAs is associated with poor prognosis. Methods: To understand the role of SCAs we performed multilocus/pangenomic analysis of 98 tumour samples from patients enrolled in the EUNB protocol. Results: Age at diagnosis was categorised into two groups using 18 months as the age cutoff. Significant difference in the presence of SCAs was seen in tumours of patients between 12 and 18 months and over 18 months of age at diagnosis, respectively ( P =0.04). A significant correlation ( P =0.03) was observed between number of SCAs per tumour and age. Event-free (EFS) and overall survival (OS) were calculated in both age groups, according to both the presence and number of SCAs. In older patients, a poorer survival was associated with the presence of SCAs (EFS=46% vs 75%, P =0.023; OS=66.8% vs 100%, P =0.003). Moreover, OS of older patients inversely correlated with number of SCAs ( P =0.002). Finally, SCAs provided additional prognostic information beyond histoprognosis, as their presence was associated with poorer OS in patients over 18 months with unfavourable International Neuroblastoma Pathology Classification (INPC) histopathology ( P =0.018). Conclusions: The presence of SCAs is a negative prognostic marker that impairs outcome of patients over the age of 18 months with localised unresectable NB without MYCN amplification, especially when more than one SCA is present. Moreover, in older patients with unfavourable INPC tumour histoprognosis, the presence of SCAs significantly affects OS.